Please login to the form below
Zeria
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Zeria's Japan sales performance.
EC approves UCB’s Fintepla to treat severe form of epilepsy
the US and Japan.
BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer
Exelixis gave Ipsen exclusive rights for the commercialisation and further clinical development of Cabometyx outside the US and Japan in 2016, and gave Takeda the rights for all future indications in ... Japan in 2017.
AstraZeneca’s heart failure treatment approved for expanded use in EU
EU, China and Japan. ... As well as this most recent EU approval, Forixga has also been approved in Great Britain, Japan and Turkey to extend the HF indication to include patients across the full spectrum
AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
Around 50, 000 people in Europe, the US and Japan and around 210, 000 people worldwide are diagnosed with the disease each year.
Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
flares in adults in major markets including the US, Japan, Mainland China and the EU,” said Carinne Brouillon, member of the board of managing directors, responsible for human pharma at BI.
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
